Lexaria Bioscience Corp

Lexaria Bioscience Corp

LEXX

Get informed when a big investor buys or sells

+ Follow
Market Cap$10.84M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Lexaria Bioscience CorpLexaria Bioscience Corp-1.1--144%--
$-1.66

Current Fair Value

397.1% downside

Overvalued by 397.1% based on the discounted cash flow analysis.

Share Statistics

Market cap$10.84 Million
Enterprise Value$5.80 Million
Dividend Yield$- (-)
Earnings per Share$-0.66
Beta0.33
Outstanding Shares24,443,846

Return

Return on Equity-144.34%ROE
Return on Assets-146.90%
Return on Invested Capital-151.38%

Valuation & Multiples

P/E Ratio-1.09P/E Ratio
PEG2.35PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue15.77
Enterprise Value to EBIT-0.61
Enterprise Value to Net Income-1
Total Debt to Enterprise0.02
Debt to Equity0.01Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
April 13, 2026
EPS Estimate
$-0.10
Average shareholder expectation
Revenue Estimate
$50,000
Average shareholder expectation

Next Earnings Call

Expected Date
July 13, 2026
EPS Estimate
$-0.06
Average shareholder expectation
Revenue Estimate
$50,000
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %6.10%▼ 1.86%
Total Invested$1.17M▲ 10.80%
Investors Holding28▲ 7.00%

ESG Score

No data

About Lexaria Bioscience Corp

3 employees

Lexaria Bioscience Corp.'s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness...